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 One RP-HPLC and two chemometric assisted UV spectrophotometric methods 
were developed and validated for the simultaneous in vitro analysis of Atrovastatin 
calcium (ATV), Ezetimibe (EZET) and Fenofibrate (FEN) in their pharmaceutical 
preparation and ternary mixtures. The chromatographic separation was achieved on 
a reversed-phase, Hypersil BDS C8 column (250X4.6 mm i.d, 5  particle size) 
with a mobile phase consisting of methanol and 0.05M phosphate buffer (pH-6.3 
adjusted with sodium hydroxide) in the ratio of (85:15)% v/v. The total run time 
was 7 min. Quantitation was achieved with UV detection at 248nm based on peak 
area. Linearity was observed over concentration range of 5 - 12µg mL
-1
 for ATV 
and EZET and 80 - 192 µg mL
-1
 for FEN. The two chemometric methods applied 
were inverse least square (ILS) and classical least square (CLS). These approaches 
were successfully applied to quantify each drug in their mixture using the 
information included in the UV absorption spectra of appropriate solutions in the 
wavelength range 220-310nm with the intervals of 5nm (Δλ = 5nm) at 19 
wavelength points. For the chemometric calibration, 18 ternary solutions were 
prepared as training set and 10 ternary solutions were prepared as validation set. 
The developed methods were successfully applied for laboratory prepared mixtures 
as well as commercial tablet formulation for ATV, EZET and FEN concentration. 
The results obtained for pharmaceutical formulation by ILS and CLS methods were 
compared with isocratic HPLC method and a good agreement was found. 
 
Please cite this article in press as Abhishek Pathak et.al. RP-HPLC and chemometric assisted UV-spectrophotometric methods for 
simultaneous in vitro analysis of atrovastatin calcium, ezetimibe and fenofibrate in their pharmaceutical formulation. Indo American Journal of 
Pharm Research.2012:2(9). 
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1. Introduction 
Atorvastatin Calcium (ATV); is chemically known as (βR, 8R)-2-(4- fluorophenyl)-α,δ-dihydroxy-5-(1-
methylethyl)-3-phenyl- 4-[(phenylamino)carbonyl]1H-pyrrole-1-heptanoic acid trihydrate. It is a synthetic 
lipid-lowering agent. ATV is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, 
the enzyme catalyzes the conversion of HMG-CoA to mevalonate an early and rate-limiting step in cholesterol 
biosynthesis 
[1-3]
. ATV stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms 
[4]
. Several analytical methods that have been reported for determination of ATV individually and in 
combination with other drugs are HPTLC 
[5-10]
, HPLC 
[10-17]
, UPLC 
[18]
 LCMS 
[19-25]
, UV-Visible 
spectrophotometry 
[26-28]
 and FT- Raman Spectroscopy 
[29-30]
. Ezetimibe (EZET); chemically (1-(4- 
flurophenyl)-3(R)- [3(S)-(4- flurophenyl) –3-hydroxy propyl] –4(S) (4 –hydroxyphenyl) azetidin- 2- one), 
which is another lipid-lowering agent. EZET belongs to a group of selective and very effective 2-azetidione 
cholesterol absorption inhibitors acts at the level of cholesterol entry into enterocytes 
[31]
. EZET has no 
inhibitory effect on absorption of lipid soluble vitamins, triglycerides or bile acids, as do statins. This distinct 
mechanism of action results in a synergistic cholesterol lowering effect when used together with statins that 
inhibits cholesterol synthesis by liver 
[32]
. Literature review reveals that methods have been reported for analysis 
of EZET by HPTLC 
[6-7]
, HPLC 
[33-36]
, LCMS 
[37-38]
 and UV-Visible spectrophotometry 
[39-40]
 for its individual 
determination and in combination with other drugs. 
Fenofibrate (FEN); chemically 2-[4-(4-chlorobenzoyl) phenoxy]-2-methyl-propanoic acid 1-methylethyl ester, 
is a lipid regulating agent. FEN is a white colored solid which is stable under ordinary conditions. It is insoluble 
in water 
[41]
. FEN is official in USP 
[42]
 and BP 
[43]
. There have been several papers on the determination of 
fenofibrate individually and in combination with other drugs using techniques such as TLC 
[44]
, HPTLC 
[45]
, 
NMR method for purity 
[46]
, HPLC 
[46-52]
, UPLC 
[18,53]
, LCMS 
[54]
, UV-Visible spectrophotometry 
[48,54-55]
 and 
capillary electrophoresis 
[56]
. Chemical structures of ATV, EZET and FEN are given in Figure 1.  
Literature revealed that for the treatment of combined hyperlipidemia and type 2 diabetes, the combined 
ATV/FEN therapy is safe and has beneficial additive effects than either treatment alone 
[57]
. In addition, the co 
administration of EZET with FEN offers a well tolerated, lipid management strategy for the patients suffering 
from mixed hyperlipidemia. The combined use of these agents provides a therapy with complementary effects 
to improve the atherogenic lipid profile observed for these patients 
[58]
. 
The combination of ATV, EZET and FEN is not official in any pharmacopoeia. One TLC 
[59]
 and two HPLC 
[60-
61]
 methods are reported for this combination but no chemometric assisted UV-spectrophotometric method is 
reported till date for the same. The objective of this report is to study the ability of ILS and CLS methods to 
estimate the mixture of ATV, EZET and FEN, whereas the zero order UV absorption spectra of ATV, EZET 
and FEN are critically interfere with each other. In addition, an economical, simple, rapid, precise, sensitive, 
selective and accurate isocratic HPLC–UV method was developed for the simultaneous determination of ATV, 
EZET and FEN in the tablet dosage form. The optimized methods were successfully applied for the 
determination of ATV, EZET and FEN in marketed preparation. The proposed HPLC method was found to be 
easy and simpler than the other reported methods for the analysis of studied drugs in their combination. The 
results obtained for the estimation of ATV, EZET and FEN in marketed preparation by ILS and CLS methods 
were compared with isocratic HPLC method and a good agreement was found. 
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Figure 1: Chemical structures of Atrovastatin Calcium (ATV), Fenofibrate (FEN) and Ezetimibe (EZET. 
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2. Experimental 
2.1. Instrumentation 
2.1.1. For HPLC 
Chromatography was performed on Shimadzu (Shimadzu Corporation, Kyoto, Japan) chromatographic system 
equipped with Shimadzu LC-20AT pump and Shimadzu SPD-20AV absorbance detector. Samples were 
injected through a Rheodyne 7725 injector valve with fixed loop at 20μl. Separation and quantitation were made 
on a reversed-phase, Hypersil BDS C8 column (250X4.6 mm i.d, 5  particle size) with a mobile phase 
consisting of methanol and 0.05M phosphate buffer (pH-6.3 adjusted with sodium hydroxide) in the ratio of  
(85:15)% v/v. Detector was set at 248nm. Data acquisition and integration was performed using Spinchrome 
software (Spincho Biotech, Vadodara). 
 
2.1.2. For chemometric spectrophotometry 
A double-beam Shimadzu UV-1700 spectrophotometer (Kyoto, Japan) connected to a computer loaded with 
Shimadzu UV Probe 2.10 software was used for all the spectrophotometric measurements. The absorbance 
spectra of the reference and test solutions were carried out in 1cm quartz cells over the range of 200-360 nm. 
The numerical calculations for ILS and CLS methods were performed by using MATLAB R2007a Software 
and Excel. 
 
2.2. Materials and Reagents 
Pure drug samples of ATV and FEN was kindly gifted by Sun Pharmaceutical, Vadodara and EZET was kindly 
gifted by ALEMBIC Pharmaceutical Ltd, Vadodara. The gift samples were used as standard without further 
purification. Double distilled water filtered through nylon filter paper 0.2 μm pore size and 47 mm diameter 
(Pall Lifesciences, Mumbai, India), was used throughout the analysis. Potassium dihydrogen orthophosphate 
and sodium hydroxide were analytical grade. Methanol used was HPLC grade and analytical grade (Qualigens 
fine chemicals, Mumbai) for HPLC and spectrophotometry, respectively. Marketed formulation Lorlip-EZ 
tablets (Unichem Laboratories Limited, India) were used for the analysis. Each tablet was labeled to contain 10 
mg ATV, 10 mg EZET and 160 mg FEN. 
 
2.3. Experimental conditions 
2.3.1. For HPLC 
The mobile phase was prepared by mixing methanol and 0.05M phosphate buffer (pH-6.3 adjusted with sodium 
hydroxide and filtered through 0.20 μm nylon filter paper) in a ratio of (85:15)% v/v and degassed. The flow 
rate was maintained at 0.8 ml min
−1
. All determinations were performed at ambient temperature. Quantitation 
based on peak area was achieved with UV detection at 248nm. The injection volume was 20 μl. 
 
2.3.2. For chemometric spectrophotometry 
The UV absorption spectra of appropriate solutions were recorded in the wavelength range 220-310nm with the 
intervals of 5nm (Δλ = 5nm) at 19 wavelength points. The scanning range selected was 200-360nm. 
 
2.4. Experimental design for ILS and CLS spectrophotometric methods 
Chemometric method or multivariate analysis was carried out using ILS and CLS methods. The methods are 
carried out in two steps. In the first step, an empirical mathematical model was built representing the 
relationship between the absorbance and concentration data generated from a set of standard samples 
(calibration set). The second step is the prediction step in which the calibration model is used to determine the 
concentration of the components (validation set) from their spectral data. The accuracy and precision of 
predictive ability of the model can be defined as root mean square error of prediction (RMSEP). A 
mathematical model is accepted if the value of RMSEP units is found to be less than three. Inverse least square 
(ILS) is the application of multiple linear regression (MLR) to the inverse expression of the Beer-Lambert’s law 
of spectroscopy. The mathematical expression is given as, 
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C= P×A…................................................................ (1) 
Where, C is the concentration matrix, A is the absorbance matrix and P is the calibration constant. The 
above equation can be written as a linear equation system as follows, C1 = P11 .A1 +P12 .A1 +….P1w +Aw, C2 = 
P21 .A1 +P22 .A2+….P2w +Aw or Cc = Pc1 .A1 +Pc2 .A2 +….Pcw +Aw, where Aw is the absorbance at 
w
th
 wavelength, Pcw is the calibration coefficient for the c
th
 component at w
th 
wavelength and Cw is the 
concentration of c
th
 component. 
The classical least square (CLS) calibration technique, based on linear CLS algorithm, involves the calculation 
of K, calibration coefficient using the absorbance data from the calibration set. The linear CLS algorithm has 
the following steps, 
A=K×C................................................................... (2) 
In this equation, A is the absorbance matrix, C is the concentration matrix and K is the calibration constant. The 
linear form of the equation can be written as, A1 = K11 .A1 +K12 .C2 +....K1c +Cc, A2 = 
K21 .A1 +K22 .C2 +....K2c+Cc, Or Aw = Kw1 .A1 + Kw2 .C2 +.... Kcw +Cc, where Aw is the absorbance at w
th 
wavelength, Kcw is the calibration coefficient for c
th
 component at w
th
 wavelength and Cc is the concentration of 
c
th
 component. 
The calibration equations (1) and (2) are used for the estimation of the amounts of components in the samples. 
The ability and efficiency of calibration was studied by estimating the standard variation of chemometric 
calibrations in case of investigated mixtures. The root mean square error of prediction (RMSEP) was calculated 
from the following formula, 
N
N
i = 1
(C i
added - C i found )
RMSEP = 
 
Where, Ci
added
 = added concentration of the drug and Ci
found
 = predicted concentration of the drug. 
 
2.5. Standard solutions and calibrations 
Stock standard solutions of ATV, EZET and FEN were prepared separately by dissolving 25 mg of each drug in 
25 ml methanol. Working standard solutions of ATV, EZET and FEN were prepared separately by transferring 
1.0 ml from stock standard solution of each drug into separate 10 ml volumetric flasks and diluted to the mark 
with methanol. Standard solutions for HPLC analysis and spectrophotometric analysis were prepared separately 
using methanol HPLC grade and methanol analytical grade respectively. 
2.5.1. For HPLC 
The solutions for calibration were prepared by further dilutions of different aliquots of the working standard 
solutions with mobile phase to reach the concentration range of 5-12 μg ml−1 for ATV and EZET and 80-192 μg 
ml
−1
 for FEN. Triplicate 20 μl injections were made for each concentration and chromatogram was obtained 
under the specified chromatographic conditions described previously. The calibration graph was constructed by 
plotting peak area versus concentration of each drug and the regression equation was calculated. Linear 
relationships were obtained. 
 
2.5.2. For chemometric spectrophotometry 
A training set (calibration set) of 18 synthetic ternary mixture solutions (Table 1) and a validation set containing 
10 synthetic ternary mixture solutions (Table 2) in the possible combinations containing 2-5 μg ml-1 of ATV and 
EZET and 8-32 μg ml-1 of FEN were prepared with methanol analytical grade using the above working standard 
solutions to develop the chemometric calibrations. The UV absorption spectra of appropriate solutions were 
recorded in the wavelength range 220-310nm with the intervals of 5nm (Δλ = 5nm) at 19 wavelength points. 
The scanning range selected was 200-360nm. The numerical calculations for ILS and CLS analyses were 
performed by using MATLAB R2007a Software and Excel. 
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2.6. Sample preparation 
Twenty tablets were accurately weighed and finely powdered. The portions of powder equivalent to 160 mg of 
FEN for HPLC and equivalent to 32mg of FEN for spectrophotometric analysis were accurately weighed and 
transferred separately into two 100ml volumetric flasks. Then 60 mL of methanol was added to each flask and 
sonicated for 15 min to solubilize the solid content. The volume was made up to the mark with methanol and 
mixed well. The sample solution for HPLC analysis and the sample solution for spectrophotometric analysis 
were filtered through 0.45 µm membrane filter and whatman filter paper no.41 respectively.  Final test solution 
for HPLC was obtained by diluting the 1.0 ml of filtrate to 10 ml with mobile phase. And the final test solution 
for spectrophotometry was obtained by diluting the 1.0 ml of filtrate to 10 ml with methanol. Final test solution 
for HPLC contained 112μg of FEN and 7μg of ATV and EZET per ml of final solution. And the final test 
solution for spectrophotometry contained 32μg of FEN and 2μg of ATV and EZET per ml of final solution. 
 
Table 1: Construction of Calibration set 
 
S. No. 
ATV 
(μg ml-1) 
EZET 
(μg ml-1) 
FEN 
(μg ml-1) 
1 4 5 8 
2 4 5 16 
3 4 5 24 
4 4 5 32 
5 3 2 16 
6 3 3 16 
7 3 4 16 
8 3 5 16 
9 2 4 32 
10 4 4 32 
11 5 4 32 
12 5 4 0 
13 5 0 32 
14 0 4 32 
15 0 0 32 
16 0 4 0 
17 5 0 0 
18 2 2 32 
 
 
2.7. Procedure for determination of ATV, EZET & FEN 
2.7.1. For HPLC 
Triplicate 20 μl injections of the appropriate solutions were injected and chromatogram was recorded under the 
specified HPLC conditions previously described in 2.3.1. The peak area values were determined and the 
concentration of each compound was calculated. 
 
2.7.2. For chemometric spectrophotometry 
The UV absorption spectra of appropriate solutions were recorded over the wavelength range of 220-310 nm 
with the intervals of 5nm (Δλ = 5nm) at 19 wavelength points. The scanning range selected was 200-360nm. 
The numerical calculations for ILS and CLS analyses were performed by using MATLAB R2007a Software 
and Excel. Concentration of each compound was calculated using each model. 
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Table 2: Construction of validation set 
S. No. 
ATV 
(μg ml-1) 
EZET 
(μg ml-1) 
FEN 
(μg ml-1) 
1 2 2 32 
2 3 2 32 
3 4 2 32 
4 5 2 32 
5 4 3 16 
6 4 4 16 
7 4 5 16 
8 5 3 8 
9 5 3 12 
10 5 3 24 
 
3. Results and discussion 
3.1. For HPLC 
The developed HPLC method has been applied for the simultaneous determination of ATV, EZET and FEN. 
The chromatographic method depends on reversed phase separation using Hypersil BDS C8 column (250X4.6 
mm i.d, 5 , particle size). The method has been optimized after studying the effect of different parameters on 
the separation. The mobile phase was chosen after several trials with methanol and buffer solutions in various 
proportions and at different pH. The studies suggested that a mobile phase consisting of methanol and 0.05M 
phosphate buffer (pH-6.3 adjusted with sodium hydroxide) in the ratio of (85:15)% v/v was found to give good 
peak shape, optimum retention and resolution of ATV, EZET and FEN on above said column at ambient 
temperature. Depending on the observations of various trials, flow rate was fixed at 0.8 ml min-1. Quantitation 
was achieved with UV detection at 248nm based on peak area. The specificity of the HPLC method is 
illustrated in Figure:2 where complete separation of the three drugs was noticed. The average retention time ± 
standard deviation (S.D.) for the ATV, EZET and FEN were found to be 3.18 ± 0.04, 4.21 ± 0.05 and 5.34 ± 
0.07 min, respectively, for 10 replicates. 
 
 
 
Figure 2: HPLC chromatogram of 20 µl injection of tablet sample containing 112μg ml-1 of FEN and 7 μg ml-1 
of ATV and EZET. 
 
3.1.1. Method validation 
3.1.1.1. Linearity and range 
Linearity study of HPLC detector response for determination of ATV, EZET and FEN was evaluated by 
analyzing a series of standard solutions of five different concentrations of each compound. Calibration curves 
constructed were linear over the concentration range of 5 –12 µg mL-1 for ATV and EZET and 80-192 µg mL-1 
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for FEN. Regression analysis has been carried out with correlation coefficient, (0.9996, 0.9994 and 0.9999), 
intercept, (- 23.29, -21.20 and 144.30) and slope (30.35, 37.61 and 21.54) for ATV, EZET and FEN 
respectively. (Table 3) 
 
3.1.1.2. Precision 
Precision was estimated by the determination of the repeatability of the method. Repeatability was assessed 
using three determinations at each of three different test concentrations (covering the specified range of the 
method), in a day for Intra-day precision and on three different days for Inter-day precision. Ternary mixtures 
containing different concentrations of ATV, EZET and FEN were prepared with mobile phase. 20 L solutions 
were injected and chromatograms were recorded. The average % RSD of intra-day and inter-day measurements 
for determination of ATV was found to be 0.578 and 0.751 respectively. For EZET % RSD of intra-day and 
inter-day measurements was found to be 0.539 and 0.658 respectively. For FEN % RSD of intra-day and inter-
day measurements was found to be 1.031 and 0.759 respectively. The values confirm the precision of the 
method. (Table 3) 
 
3.1.1.3. Accuracy 
Accuracy of the method was confirmed by recovery study from prepared Laboratory sample at 3 level of 
standard addition (80%, 100%, and 120%) of label claim. No interference could be observed with the proposed 
methods.  The mean percentage recoveries were found to be 100.31±0.30 %, 100.09±0.13 % and 100.27±0.36 
% for ATV, EZET and FEN, respectively. The excellent recoveries of standard addition method with low SD 
justified the high accuracy of the proposed method. (Table 3) 
 
3.1.1.4. Detection and Quantitation limits 
Calibration curve was repeated for 3 times and the standard deviation (SD) of the intercepts was calculated. 
According to ICH recommendations (1996) 
[62]
, the approach based on the S.D. of the response and the slope 
was used for determining the limit of detection (LOD) and limit of quantitation (LOQ). The LOD and LOQ 
were measured as follows. 
LOD=3.3 * SD/slope of calibration curve 
LOQ=10 * SD/slope of calibration curve 
SD = Standard deviation of intercepts 
The theoretical values were assessed practically. The detection limits were found to be 0.54, 0.56 and 5.08 µg 
mL
-1 
for ATV, EZET and FEN, respectively. The quantitation limits were found to be 1.79, 1.74 and 15.38 µg 
mL
-1
 for ATV, EZET and FEN, respectively. (Table 3) 
 
3.1.1.5. Robustness 
To evaluate robustness of the method few parameters were deliberately varied. The parameters included 
variation of flow rate by ± 0.1, change in pH of buffer by ± 0.2, two different instruments and methanol of two 
different manufacturers. The average value of % RSD for determination of ATV, EZET and FEN less than 2 % 
revealed the robustness of the method. 
 
3.1.1.6. Stability 
The standard and sample solutions of ATV, EZET and FEN in methanol and mobile phase were stored at room 
temperature for 24hrs and at 5 °C in refrigerator for 4 days.  These stored solutions were injected in to LC 
system. No additional peak found in chromatogram indicating the stability of ATV, EZET and FEN in the 
standard and sample solutions. 
3.1.1.7. Specificity 
According to ICH document for specificity (1996) 
[62]
, the method is specific when the results are unaffected by 
the presence of the dosage form excipients, so the above results demonstrated the specificity of the method. 
Furthermore, the specificity of the proposed HPLC method was confirmed by comparing the chromatograms of 
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standards and sample solutions. The average retention times ± standard deviation for ATV, EZET and FEN in 
the tablets were found to be 3.18 ± 0.04 min [3.19 ± 0.06 min for standard ATV], and 4.21 ± 0.05 min 
[4.22±0.04 min for standard EZET] and 5.34 ± 0.07 min [5.35 ± 0.03 min for standard FEN] for ATV, EZET 
and FEN respectively. 
 
Table 3: Summary of validation parameters for the proposed HPLC method for the determination of ATV, 
EZET and FEN 
No. Parameters 
HPLC 
ATV EZET FEN 
1. Linearity range (µg mL
-1
)  5-12 5-12 80-192 
2. Slope  30.35 37.61 21.54 
 ±SD  0.03 0.09 0.09 
 % RSD 0.11 0.25 0.43 
 Standard error 1.36 × 10
-2 
3.84 × 10
-2
 3.78 × 10
-2
 
3. Intercept (% RSD) -23.29 -21.20 144.30 
 ±SD  0.08 0.11 0.85 
 % RSD  0.34 0.51 0.59 
 Standard error  3.23 × 10
-2
 4.41 × 10
-2
 34.76 × 10
-2
 
4. Correlation coefficient  0.9996 0.9994 0.9999 
 ±SD 8.4×10
-4 
5.0×10
-4
 7.0×10
-4
 
 %RSD 0.08 0.05 0.07 
 Standard error 3.4×10
-4
 2.0×10
-4
 2.7×10
-4
 
5. LOD (µg mL
-1
)  0.54 0.56 5.08 
6. LOQ (µg mL
-1
)  1.79 1.74 15.38 
7. Accuracy (%) 100.31 100.09  100.27  
 ± SD 0.30 0.13 0.36 
 %RSD 0.30 0.13 0.36 
 Standard error 0.12 0.05 0.15 
8. % RSD of Intra-day precision* 0.578 0.539 1.031 
9. % RSD of Inter-day precision *  0.751 0.658 0.759 
*mean value of precision of six determinations 
 
3.1.1.8. System suitability 
Theoretical plates per meter ± RSD, Theoretical plates per column ± RSD, capacity factor, selectivity (α), 
symmetry factor and resolution for ATV, EZET and FEN in the sample solution were calculated for system 
suitability of HPLC method. Satisfactory results were obtained. (Table 4) 
 
Table 4: Results of system suitability parameters for the proposed HPLC method for the determination of ATV, 
EZET and FEN 
No. 
Parameters 
Data obtained 
ATV EZET FEN 
1. Theoretical plates per meter 92794 85084 118137 
 % RSD 0.45 0.85 0.14 
2. Theoretical plates per column 4640 4254 5907 
 % RSD 0.64 0.24 0.65 
3. Capacity factor 2.85 1.12 1.65 
4. Selectivity(α) 2.544 1.272 2.152 
5. Symmetry factor/Tailing factor 1.257 1.122 0.873 
6. Resolution  4.417 4.431 
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3.2. For chemometric spectrophotometry 
Figure 3 shows the overlain zero-order absorption spectra of ATV, EZET and FEN and their ternary mixture 
solution in methanol in the 200-400 nm absorption region.  
 
 
Figure 3: overlain zero-order absorption spectra of 2 µg ml
-1
 ATV, 2 µg ml
-1
  EZET and 32 µg ml
-1
  FEN and 
their ternary mixture (containing 2 µg ml
-1
 ATV, 2 µg ml
-1
  EZET and 32 µg ml
-1
  FEN) solution in methanol. 
The zero-order absorption spectra (Figure 3) of ATV, EZET and FEN completely overlap with each other that 
makes impossible to use the conventional spectrophotometric methods to analyze the compounds in presence of 
each other. For example, the zero-crossing technique is not suitable for the resolution of ternary mixture. There 
are some methods to obviate this kind of problem in ternary mixtures like simultaneous application of division 
and derivation of the absorption spectra, application of double divisor method and the concept of mathematical 
modeling based on multivariate calibration 
[63-66]
.  Thus the ILS and CLS chemometric spectrophotometric 
methods were found to be appropriate for determination of ATV, EZET and FEN in ternary mixture. A training 
set (calibration set) of 18 synthetic ternary mixture solutions (Table 1) and a validation set containing 10 
synthetic ternary mixture solutions (Table 2) in the possible combinations with methanol analytical grade were 
prepared. The UV absorption spectra of appropriate solutions were recorded in scanning range of 200-360nm 
and the wavelength range selected was 220-310nm with the intervals of 5nm (Δλ = 5nm) at 19 wavelength 
points. 
 
3.2.1. ILS method 
In this method, the coefficient matrix (P) was obtained from the linear equation system using the absorbance 
data and the calibration set. Introducing (P) into the linear equation system we obtain the calibration for ILS as: 
19A
18A
17A
16A
15A
14A
13A
12A
11A
10A
9A
8A
7A
6A
5A
4A
3A
2A
1A
017.0026.0035.0042.0045.0045.0043.0042.0040.0039.0038.0034.0028.0022.0009.0020.0025.0031.0035.0
0002.00003.00006.00006.00002.0003.0005.0006.0007.0009.0013.0022.0029.0034.0036.0039.0039.0031.0023.0
002.0004.0007.0010.0013.0016.0019.0022.0024.0026.0030.0033.0035.0035.0035.0032.0029.0027.0027.0
FENC
EZETC
ATVC
 
In this calibration, CATV, CEZET and CFEN are the concentration of ATV, EZET and FEN, respectively. The 
observed absorbance values of the compounds in the ternary mixture solutions, at the 19 wavelength points in 
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the spectral region from 200nm to 360nm, were replaced in the above equation and the amount of ATV, EZET 
and FEN in the synthetic mixtures and tablets were calculated. 
 
3.2.2. CLS method 
In this method, the coefficient matrix (K) was calculated by using the linear equation system between the 
absorbance data and training set. Replacing the coefficient matrix (K) into the linear equation system, the 
calibration of CLS can be written as: 
FENC
EZETC
C
0174.00002.00021.0
0261.00003.00042.0
0351.00006.00067.0
0419.00002.00097.0
0447.00027.00129.0
0450.00048.00161.0
0432.00061.00189.0
0415.00065.00217.0
0399.00091.00240.0
0390.00134.00264.0
0379.00215.00296.0
0343.00294.00328.0
0284.00337.00351.0
0222.00346.00359.0
0187.00356.00346.0
0203.00393.00316.0
0249.00386.00287.0
0309.00308.00267.0
0349.00227.00274.0
19A
18A
17A
16A
15A
14A
13A
12A
11A
10A
9A
8A
7A
6A
5A
4A
3A
2A
1A
ATV
 
 
 
Where, CATV, CEZET and CFEN are the concentrations of ATV, EZET and FEN, respectively. The observed 
absorbance values of the compounds in the ternary mixture solutions, at the 19 wavelength points with the 
interval of 5nm (Δλ = 5nm) in the spectral region from 200nm to 360nm, were replaced in the above equation 
and the amount of ATV, EZET and FEN in the synthetic mixtures were calculated. 
The tested mixtures for ILS and CLS were subjected to recovery studies. The results obtained were good. These 
results, % recoveries and standard deviation are shown in (Table 5). The ILS and CLS models were then applied 
to estimate ATV, EZET and FEN in commercial tablet preparations. The results are shown in (Table 7). The 
numerical values of all statistical parameters (Table 6) indicated that the proposed techniques are suitable for 
the determination of these drugs in the tablet formulation as excipients do not interfere. 
 
3.3. Analysis of commercial tablet preparation 
The proposed multivariate ILS and CLS spectrophotometric methods and HPLC method were applied to the 
simultaneous determination of ATV, EZET and FEN in commercial Lorlip-EZ tablet preparations. Satisfactory 
results were obtained for each compound which were in good agreement with label claim. The assay results of 
the proposed ILS and CLS spectrophotometric methods were compared to those of the proposed HPLC method. 
The results obtained were statistically analyzed and compared using paired t-test and F-test at 95% confidence 
level. The results are shown in Table 7. The calculated values did not exceed the theoretical ones; indicating 
that there was no significant difference between the methods compared. 
 
 
 
 
                                                   Indo American Journal of Pharmaceutical Research, 2012:2(9)                        ISSN NO: 2231-6876 
 
ww.iajpr.com 
P
ag
e1
1
8
8
 
 
Table 5: Percentage recovery results of ATV, EZET and FEN in synthetic mixtures (validation set) by the 
proposed ILS and CLS chemometric methods 
 
Mixture 
composition 
(µg ml
-1
) 
 
% recovery 
ILS 
 
CLS 
N
o. 
A
T
V 
EZ
ET 
FE
N 
AT
V 
EZE
T 
FEN AT
V 
EZE
T 
FEN 
1 2 2 32  101.
1 
100.
83 
99.9
3 
 99.6
7 
100.
2 
100.
71 2. 3 2 32  100.
31 
99.6
9 
100.
52 
 99.4
3 
99.6
6 
100.
03 3. 4 2 32  99.9
7 
100.
8 
99.8
5 
 100. 
5 
100.
1 
99.9
3 4. 5 2 32  100.
59 
99.9
4 
100.
14 
 101.
01 
100.
68 
99.1
7 5. 4 3 16  100.
11 
99.8
7 
99.9
5 
 99.9
1 
99.9
2 
99.9
8 6. 4 4 16  99.9
5 
100.
08 
100.
16 
 101.
24 
100.
73 
99.9
6 7. 4 5 16  101.
05 
99.9
1 
99.8
8 
 101.
09 
100.
05 
100.
2 8. 5 3 8  1 0.
09 
101.
02 
101.
04 
 99.7
2 
99.9
4 
101.
06 9. 5 3 12  99.7
8 
99.9
7 
99.9
8 
 100.
91 
100.
39 
99.9
3 10
. 
5 3 24  100.
36 
100.
51 
100.
18 
 10 .
04 
99.5
4 
100.
08 Mean 
               ±SD 
100.
33 
100.
26 
100.
16 
 1 0.
45 
100.
12 
1 0.
11 0.45 0.48 0.37  0.69 0.39 0.50 
Variance (SD) 0.21 0.23 0.13  0.48 0.15 0.25 
% RSD 0.45 0.48 0.37  0.69 0.39 0.50 
Standard error 0.18 0.19 0.15  0.28 0.16 0.20 
 
Table 6: Statistical parameters of ATV, EZET and FEN in synthetic mixtures (validation set) using the 
proposed ILS and CLS chemometric methods 
 
No
. 
Statistical 
parameters 
 ILS  CLS 
 ATV EZET FEN  ATV EZET FEN 
1. Range (µg ml
-1
)  2-5 2-5 8-32  2-5 2-5 8-32 
2. Slope  1.000 1.004 0.999  0.998 1.023 0.999 
 ±SD   6.5×10
-3     1.9×10
-
3
 
2.1×10
-3
         2×10
-
3
 
0.98×10
-3
 1.7×10
-3
 
 %RSD  0.65 0.19 0.21  0.20 0.09 0.17 
 Standard error  2.7×10
-3 
8.0×10
-4 
8.7×10
-4 
 8.2×10
-4 
4.0×10
-4 
6.8×10
-4 
3. Intercept  0.03 0.04 0.043  0.029 0.042 0.03 
 ±SD  1.9×10
-4
 1.9×10
-4
 1.0×10
-4
  1.5×10
-4
 2.1×10
-4
 0.7×10
-4
 
 %RSD  0.63 0.47 0.23  0.57 0.50 0.23 
 Standard error 
  
Intercept 
 7.7×10
-5 
7.8×10
-5 
4.1×10
-5 
 6.1×10
-5 
8.6×10
-5 
2.9×10
-5 
4. Correlation 
coeffici n
 0.999 0.999 1.000  0.999 1.000 0.999 
 ±SD   1.1×10
-3
 1.4×10
-3
 0.9×10
-3
  1.4×10
-3
 1.3×10
-3
 1.4×10
-3
 
 %RSD  0.11 0.14 0.09  0.14 0.13 0.14 
 Standard error 
 
 4.5×10
-4 
5.8×10
-4 
3.6×10
-4 
 5.8×10
-4 
5.1×10
-4 
5.8×10
-4 
5. Accuracy (%)  100.21 100.26 100.16  100.45 100.04 100.31 
 ±SD  0.45 0.48 0.37  0.74 0.39 0.45 
 %RSD  0.45 0.48 0.37  0.74 0.39 0.45 
 Standard error 
  
Intercept 
 0.08 0.08 0.06  0.12 0.06 0.08 
6. RMSEP  0.034 0.024 0.045  0.035 0.043 0.059 
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Table 7:  Assay results of the commercial tablet preparation (Lorlip-EZ) by the proposed ILS, CLS 
chemometric methods and HPLC method     
 
Formulation  Lorlip-EZ 
Method  ILS  CLS  HPLC 
Drugs  ATV EZET FEN  ATV EZET FEN  ATV EZET FEN 
Label claim 
(mg/tab) 
(mg/tablet) 
 10 10 160  10 10 160  10 10 160 
Amount found* 
) 
 10.029 10.017 159.712  10.056 9.985 159.996  10.025 9.985 160.067 
% Assay  100.29 100.17 99.82  100.56 99.85 99.99  100.25 99.95 100.04 
± SD  0.32 0.27 0.19  0.53 0.16 0.25  0.15 0.18 0.09 
% RSD  0.32 0.27 0.19  0.53 0.16 0.25  0.15 0.18 0.09 
Standard Error   0.13 0.11 0.08  0.22 0.07 0.10  0.06 0.07 0.04 
t-value  0.959 0.737 0.624  0.683 0.884 0.882  (2.571)
# 
(2.571)
#
 (2.571)
#
 
F-value  0.360 0.332 0.068  0.015 0.597 0.173  (5.050)
† 
(5.050)
†
 (5.050)
†
 
* Mean amount found of six determinations 
# Theoretical t- value at p=0.05 and 95% confidence level 
† Theoretical F- value at p=0.05 and 95% confidence level 
 
4. Conclusion 
RP-HPLC techniques are generally used for separation and determination of components in final 
pharmaceutical preparations and are superior with regard to identification and specificity. However, the 
chemometric methods are less expensive by comparison and do not require sophisticated instrumentation nor 
any prior separation step. The proposed chemometric-assisted spectrophotometric methods are applicable, 
prompt, and specific for the simultaneous determination of ATV, EZET and FEN in their synthetic mixtures and 
commercial pharmaceutical tablets. The results obtained were compared with the proposed RP-HPLC method 
and good coincidence in the means of recovery was observed as there was no significant difference between the 
methods compared. The three proposed methods were accurate, precise with good reproducibility and 
sensitivity; hence can be used for the routine analysis of ATV, EZET and FEN in their combined 
pharmaceutical formulations. 
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